Background: Since 1985, we introduced a modified combination of etoposide, ifosfamide, and cisplatin (PEI) as second-line therapy of adult male germ cell tumors with the aim to reduce toxic effect while maintaining efficacy over the original regimen.
introduction First-salvage chemotherapy for relapsing or progressing male germ cell tumors (GCT) is a debated issue as neither a standard regimen nor a superior strategy between conventional dose (CDCT) and high-dose chemotherapy (HDCT) was definitely established. Since the early 1990s, available options for secondline attempt are constituted by the combination of cisplatin and ifosfamide with either etoposide (VIP) or vinblastine (VeIP) [1] [2] [3] [4] [5] [6] [7] . Results of these regimens are obtained from long-dated series consisting of small number of patients and comparing across studies is fraught with difficulty, either when focusing on efficacy outcomes or even more when dealing with safety and toxic effect. Taken together, regimens conventionally used in the pre-taxane era resulted in a complete response (CR) rate in the range of 35%-50% and a maintained CR-rate approximating 20%-25%. Very promising results were further reported with the introduction of paclitaxel in combination with ifosfamide and cisplatin (TIP) in a selected population of 46 patients with good clinical features as 70% of CR were obtained, 65% of patients being progression-free at 2 years [8] . In the second half of the 1980s, we treated a pilot cohort of 36 consecutive male patients with a modified VIP regimen with the aim to reduce toxic effect while preserving activity over the original regimen. Ifosfamide was given at a reduced dose (2.5 g/m 2 ) the first 2 days followed by a slightly reduced total dose of etoposide (100 mg/m 2 ) combined with a slightly increased dose of cisplatin (40 mg/m 2 ) given for the remaining three days. Substitution of etoposide with vinblastine (PVI) at the dose of 6 mg/m 2 was provided in this series to patients pretreated with cisplatin, etoposide, and bleomycin (PEB). Overall side-effects were moderate and a maintained remission rate of 42% was obtained, that improved to 70% for those who had responded to primary chemotherapy, at a long-term follow-up [9] . PVI was abandoned after the first eight patients due to poor activity. We then further modified VIP combination by reducing the dose of cisplatin as described below and since then this regimen, called PEI combination, was actually introduced as the second-line therapy at Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
materials and methods
Since 1985, PEI chemotherapy was administered in all consecutive patients failing first-line regimen consisting of at least three cycles of the combination of cisplatin and bleomycin plus either etoposide (PEB) or vinblastine (PVB), followed by surgery in all eligible cases. Regimen consisted of the administration of ifosfamide at the dose of 2.5 g/m 2 on days 1 and 2 (with intravenous mesna protection at 600 mg/m 2 q6 h days 1,2) followed by cisplatin at 33 mg/m 2 and etoposide at 100 mg/m 2 both on days 3-5. Granulocyte-or granulocyte-macrophage colony-stimulating factor (G-CSF or GM-CSF) were administered following chemotherapy in case of grade 3-4 neutropenia up to November 2008. Since then, prophylactic use of pegylated G-CSF (Peg-GCSF) was administered on day 6 of each cycle as a standard policy. Program provided four cycles of PEI every 3 weeks, followed by surgery in all responding cases with resectable disease. Baseline assessments included serum tumor markers [STM, alpha-fetoprotein (AFP), beta-human choriogonadotropin (HCG), and lactate dehydrogenase], and a total body computed tomography scan, to be repeated before each cycle (STM), and after two cycles and at the end of treatment (radiologic restaging). A CR was defined as a complete disappearance of all clinical, radiographic, and biochemical evidence of disease for a minimum of 4 weeks. A partial response with negative markers (PRm−) was defined as a normalization of tumor markers without surgery of residuals while a PR-positive markers (PRm+) was defined as an incomplete marker negativization in patients without a surgical procedure for a residual mass. PRm− patients undergoing surgery were further categorized as having fibrosis and necrosis, viable residual tumor, or teratoma. Stable disease (SD) was defined in all cases which were not deemed to be judged as response nor as disease progression. Patients who achieved a CR, PR, or SD were not considered to have had an event in the progression-free survival (PFS) analysis until they developed evidence of disease progression, defined by rising STM, increasing size of nonteratomatous tumor masses or development of new tumor masses. Disease was considered cisplatin refractory when at least tumor stabilization or a remission had been achieved, but tumor progression occurred again within four weeks of the last cisplatin administration. Disease progressing under chemotherapy was defined as absolutely refractory. Side-effects were graded according to the updating versions of the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) [10] .
statistical analysis
Tumor response to treatment was assessed according to the intent-totreat principle and two patients with missing information were considered as failures. Exact 95% confidence interval (CI) of response proportion was calculated based on the binomial distribution.
Event times were calculated starting from the date of PEI chemotherapy initiation up to the date of event occurrence, and censored at the date of last contact for event-free patients. For each end point, survival curves were obtained with the Kaplan-Meier method considering the overall series or with stratification for the International Germ Cell Consensus Classification Group-2 (IGCCCG-2) risk score [11] , and the log-rank test was used for comparison across different risk categories. A Cochran-Armitage test for trend was used to assess the association between response rate (CR and PRm−) and IGCCCG-2 risk category. Multivariable analysis based on Cox regression models was also undertaken to evaluate the prognostic effect of the following prespecified factors: tumor primary site, Memorial Sloan-Kettering Cancer Center (MSKCC) risk category (good versus poor) [8, 12] , IGCCCG prognostic category [13] , IGCCCG-2, late relapse, presence of liver, bone, or brain (LBB) metastases, value of elevated markers at relapse, and response to first-line therapy (CR or PRm− versus incomplete response). Because of the strong correlation between IGCCCG and IGCCCG-2, these two factors were alternatively entered into the Cox models.
The analyses were carried out using the SAS® and R software (http://www. r-project.org/, last access 20 December 2012), and the results were considered statistically significant whenever a two-sided P-value below 5% was achieved.
results
From February 1985 to January 2012, 189 consecutive patients were treated after failure of either PVB (N = 25) or PEB (N = 164). Table 1 presents their principal characteristics; briefly, median age was 30 years (IQR: 25-35), 31 of them (16.7%) were late relapses, 13 (6.9%) had a primary mediastinal GCT, and 72.6% of them presented with IGCCCG-2 intermediate-to-very high-risk score, 41 (21.7%) had LBB metastases, and 28 (14.8%) had a cisplatin resistant disease (e.g. had a refractory or absolutely refractory disease). Median number of administered cycles was 4 (IQR: 3.4) and no permanent discontinuations due to toxic effect were observed. Eighty-one patients (42.9%) had a dose reduction of one drug (N = 47) or more (N = 34) for at least one cycle, 78% of them being treated before 2000. Most frequent reduction consisted of the administration of ifosfamide at the 75%-80% of total dose, either alone (N = 41) or with concomitant reduction to 75% cisplatin (N = 11). CR to chemotherapy was achieved in 35 patients (18.5%; 95% CI 13.3% to 24.8%) while 67 patients (35.4%; 95% CI 28.6% to 42.7%) obtained a PRm−, 41 of them being radically resected. Therefore, the resulting total diseasefree (NED) rate after chemotherapy plus surgery was 40.2% (95% CI 33.2% to 47.6%, Table 2 ). Fourteen patients (7.4%) yielded neither evidence of residual disease nor teratoma in the resected tissue. Responses ranged between 23.5% in the very high-risk category to 72.7% in the very low-risk one (P < 0.001).
Median follow-up was 122.1 months (IQR: 71.4-232.0). A total of 133 progressions and 114 deaths were recorded. Median PFS was 7.2 months (95% CI 6.2-9.5) while 2-year PFS was 34.3% (95% CI 28.1% to 41.9%). Median survival was 21.7 months (95% CI 16.7-69.5) while 5-year overall survival (OS) was 42.1% (95% CI 35.3% to 50.2%) ( Table 3 and Figure 1A and B). Two-year PFS ranged from 63.6% (95% CI 40.7% to 99.5%) in the very low-risk category to 5.5% (95% CI 0.8% to 37.3%) in the very high-risk one while five-year OS ranged 72.7% (95% CI 50.6% to 100.0%) to 5.6% (95% CI 0.8% to 37.3%). Differences across IGCCCG-2 categories were statistically significant (P < 0.001) (Table 3, Figure 1C and D 
discussion
To the best of our knowledge, this is the largest series relative to a single-salvage chemotherapy regimen for patients with GCT, including HDCT experiences. Despite the shortcomings attributable to the long-dated series and the retrospective quality, results should be viewed in the light of continuing improvements of supportive care and the use of myeloid growth factors, and one may argue that the side-effect rate, as well as the yet relatively high dose intensity we achieved, might be further improved in the prospective population.
Retrospective bias may particularly reflect on toxic effect reporting as side-effects were not uniformly and thoroughly evaluated outside of a clinical trial setting. This may result in underestimating events and under-representing extrahematologic toxic effect, and this is the reason why we reported on the severe side-effects only. Of note, reduction in dose of ifosfamide and etoposide compared with the original schedules determined a very low rate of febrile neutropenia and extra-hematologic toxic effect, particularly regarding neurologic and renal side-effects. A comparison of side-effects across different regimens is very hard and perhaps the benchmark is provided by the standard-dose arm (VIP/VeIP) of the IT-94 trial [14] . In the 136 patients of the latter, an overall rate of 88.2% and 55.6% of severe neutropenia and thrombocytopenia, respectively and 49.3% of febrile neutropenia were reported, far beyond what we reported with PEI through the years. Moreover, four toxic deaths were observed in this arm.
As for the efficacy results achievable with CDCT in the pure second line, the options currently available and based on large series are relative to VeIP chemotherapy on 135 patients, and the standard-dose arm regimen of the IT-94 trial on 136 [2] , 40 (1990) [5] , 30 (1991) [3] , 54 (1996) [6] , and 56 (1997) [7] . Since the introduction of a paclitaxel-containing regimen (TIP) in recent years, this was felt as the most suitable option for patients not cured by PEB but, again, information available is relative to 46 patients only and with good prognostic features as they were selected among those with favorable prognosis according to original articles Annals of Oncology MSKCC [8] . Of note, a multicenter British Medical Research Council-sponsored trial using a modified TIP schedule with a slight reduction in paclitaxel total dose mirrored the results of the pre-taxane era in an unselected patient population [15] . In the last years, the renaissance of the salvage HDCT approach basically entailing the administration of a double course of highdose carboplatin and etoposide or three-courses of the same combination preceded by an induction with two cycles of paclitaxel and ifosfamide (TI-CE) raised the need for a reassessment of the first-salvage strategy [16, 17] . Actually, up to 70% of second-line and 50% of multirelapsing/refractory patients benefited from durable responses in Einhorn's series while 5-year PFS and OS with TI-CE were 48 and 52%, respectively. The major pitfall when considering possible implications of the use of HDCT in an earlier disease setting (e.g. the first-salvage attempt) is the lacking evidence of superiority coming from a randomized trial. Yet, the only randomized trial comparing four cycles of VIP/VeIP to three cycles of the same chemotherapy followed by one HDCT course with carboplatin, etoposide, and cyclophosphamide (CarboPEC) failed to meet the primary efficacy end point [14] . The availability of new prognostic categories (very low risk, low risk, intermediate risk, high risk, and very high risk) in the second-line setting currently allows a more reliable comparison and stratification of results not only between the two treatment modalities but also within each one of them. For our purposes, the benchmark for CDCT was taken from the retrospective international comparison of conventional dose versus HDCT including a multiplicity of regimens [18] . Survival estimates in terms of 2-year PFS and 5-year OS in the different prognostic categories are open to discussion. Of note, efficacy with PEI compares favorably with that reported in almost all IGCCCG-2 risk categories: in particular, 2-year PFS with PEI is of 23.1% and 5.5% in the high-to very highrisk categories compared with 17.2% and 1.9%, while 5-year OS is 34.0% and 5.6% versus 23.0% and 3.4%, respectively. In the category of high-risk patients, results are comparable with those reported with the use of a HDCT strategy. Looking again at the IT-94 cohort, a similar rate of CR was achieved (23% versus 18.5% with PEI) but a lower rate of PRm− (17% versus 35.4% with PEI) with comparable survival outcomes. Unfortunately, a categorization of results according to IGCCCG-2 score is not available in Einhorn's and TI-CE series.
Taken together, these results confirmed the good premises we achieved in the pilot population of patients and lended support to the rationale of modifying the original VIP schedule in order to improve tolerability while preserving (or perhaps improving) efficacy. Interestingly, despite we initially reported poorer results in the cohort of patients who were cisplatin refractory, efficacy in the present series seems to be maintained even in the categories of patients at higher risk. At MVA, the presence of LBB metastases confirmed as one of the most negative prognostic factors of either PFS or OS. Moreover, a trend toward a poorer prognosis was observed for patients presenting with high levels of AFP (95% CI levels at the limit of significance for PFS and a hazard ratio of 2.78 for OS, with a 95% CI value of 5.14 at the upper bound).
It is commonly perceived that, in the absence of a randomized comparison, it will be impossible to drive a roadmap for the first-salvage setting. If tandem or triple courses of high-dose carboplatin and etoposide seem recommended options, the excellent tolerability and good efficacy of the modified PEI regimen described here prompt its use as a convenient alternative to similarly effective, yet more toxic salvage regimens. Consistency of results in relation to the sample size provides a compelling argument for a randomized comparison with either a CDCT regimen or HDCT.
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